NGM Biopharmaceuticals Q4 EPS $(0.33) Beats $(0.39) Estimate, Sales $165.00K Miss $560.00K Estimate

3/11/24 4:20:24 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NGM alert in real time by email

NGM Biopharmaceuticals (NASDAQ:NGM) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 26.67 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $165.00 thousand which missed the analyst consensus estimate of $560.00 thousand by 70.54 percent. This is a 99.09 percent decrease over sales of $18.18 million the same period last year.

Get the next $NGM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NGM

Date	Price Target	Rating	Analyst
3/12/2024		Outperform → Mkt Perform	Raymond James
2/28/2024		Outperform → Market Perform	TD Cowen
2/27/2024		Buy → Neutral	Citigroup
5/3/2023	$6.00	Buy	Citigroup
10/18/2022	$29.00 → $4.00	Buy → Neutral	Goldman
10/18/2022	$42.00 → $4.00	Strong Buy → Outperform	Raymond James
10/17/2022		Buy → Hold	Jefferies
10/17/2022		Overweight → Neutral	Piper Sandler

More analyst ratings

$NGM
Press Releases

Fastest customizable press release news feed in the world

NGM Bio Announces Closing of Tender Offer
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. ("Parent"), an affiliate of The Column Group, LP ("TCG"), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. ("Merger Sub"), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain other stockholders at a price per share of $1.55 in cash (the "Offer Price"). The tender offer and related withdrawal rights expired at one minute a
4/5/24 9:19:51 AM ET
$NGM
Biotechnology: Pharmaceutical Preparations
Health Care
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA. Poster Presentation Details: Title: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose esca
3/19/24 5:30:44 PM ET
$NGM
Biotechnology: Pharmaceutical Preparations
Health Care
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravidarum (HG) by the end of 2024-- --Ongoing discussions with regulators on the design of a potential registrational trial of aldafermin, an engineered FGF19 analog, for the treatment of primary sclerosing chola
3/11/24 4:05:00 PM ET
$NGM
Biotechnology: Pharmaceutical Preparations
Health Care

$NGM
Leadership Updates

Live Leadership Updates

NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engineered FGF19 analog product candidate, compared to patients treated with placeboInitiated the first two Phase 2b expansion cohorts in the Phase 1/2 trial evaluating NGM707, an ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab)Announced the appointment of Dan Kaplan, Ph.D. to Chief Scientific OfficerExtended expected cash runway into the second quarter of 2025 following a restructuring o
5/4/23 4:05:00 PM ET
$NGM
Biotechnology: Pharmaceutical Preparations
Health Care
Marathon Health Expands Board of Directors
INDIANAPOLIS, Feb. 8, 2022 /PRNewswire/ -- Marathon Health announces the addition of four members to its Board of Directors, as the company continues to accelerate plans to achieve its mission of fixing the U.S. health system by scaling its advanced primary care model. Ms. Obi Felton, Ms. Siobhan Nolan Mangini, Dr. Glenn Steele and Mr. Bill Whitely bring a strong and diverse set of track records and experience, spanning leadership in clinical quality, patient experience, technology, and rapid growth. Marathon's appointment of these four Directors comes at an exciting inflecti
2/8/22 7:00:00 AM ET
$NGM
Biotechnology: Pharmaceutical Preparations
Health Care
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results
Completed enrollment in 320-patient Phase 2 CATALINA study of NGM621, an anti-complement C3 antibody, for the treatment of geographic atrophy; topline data expected in second half of 2022Initiated a Phase 1/2 clinical trial of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumorsAmended collaboration with Merck to focus primarily on advancing novel medicines for retinal and cardiovascular and metabolic diseases; NGM gained worldwide rights to its disclosed oncology portfolio as well as additional assets falling outside of the amended collaboration's narrower scope$390.6 million in cash, cash equivalents and marketable securities as of June 30, 2021 SOUTH SAN
8/5/21 4:05:00 PM ET
$NGM
Biotechnology: Pharmaceutical Preparations
Health Care

NGM Biopharmaceuticals Q4 EPS $(0.33) Beats $(0.39) Estimate, Sales $165.00K Miss $560.00K Estimate

Chat with this insight

Recent Analyst Ratings for $NGM

$NGM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Tcg Opportunity Iii Gp, Llc returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

Column Group Gp, Lp returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

Column Group L P returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

$NGM Market Insights

Live Market Insights

NGM Bio To Present Two Posters Highlighting Clinical Data From Ongoing Phase 1/2 Clinical Trial Of NGM707, A Dual ILT2/ILT4 Antagonist Antibody Product Candidate, At AACR 2024 Annual Meeting

Raymond James Downgrades NGM Biopharmaceuticals to Market Perform